Sympathetic nervous signaling dictates prostate cancer progression

D. Sigorski1,2 and E. Iżycka-Świeszewska3

© The Author(s) 2022

Cell Death Discovery (2022) 8:109; https://doi.org/10.1038/s41420-022-00928-3

Many different signaling pathways and biological mechanisms regulate the growth and development of cancer. The tumoral neural microenvironment and altered neurosignaling constitute a new hallmark of cancer merging as new targets for oncological therapy [1]. Nervous system involvement in tumorigenesis, cancer progression, and metastases is actively studied in prostate cancer (PCa). In the last issue of Cell Death Discovery, Dwivedy et al. showed their results of studies on adrenergic innervation and its contribution to neuroendocrine differentiation, one of the mechanisms of the castration-resistant phase of PCa (CRPC).

Dwivedy et al. studied the role of β-blockers in the inhibition of neuroendocrine PCa transformation as a possible therapeutic approach [1] (ref. [2]).

The authors showed that sympathetic axons were present within the tumor microenvironment and interacted with neoplastic cells [2]. They found the increased innervation in half of the examined tumors, interpreting that as the evidence of active axonogenesis. The authors calculated the number of nerve fibers in the tumor and adjacent tissue, but the exact methodology including measurement area and magnification was not specified. In addition, the examined group of PCa samples was limited to only eight. Moreover, the selection criteria of the cases, as well as important data on the interval between prostatectomy and the development of metastases and castration resistance were not provided. Importantly, translation research on neuroendocrine PCa needs a large study population to get valuable results, especially since it concerns only 10% of CRPC cases. Dwivedy et al. demonstrated that sympathetic innervation was higher in some PCa than in normal adjacent tissue. The direct comparison of this research with the literature on PCa innervation/axonogenesis is impossible, and conclusions seem to be unequivocal.

The presence of nerve branches and the intratumoral axonal network partially come from axonogenesis and neurogenesis [3]. Diverse tissue distribution of autonomic nerve fibers, creating many forms and relations with cancer cells have been reported previously [4–6]. Nerve density (ND) is a recently used marker for the assessment of innervation, but its results are difficult to compare. ND depends on the type, quantity and quality of examined tissue, calculating method, sensitivity and specificity of the used neural markers, and the individual definition of ND. Magnon et al., in their seminal ND study, showed that the overall ND was higher in high-risk PCa than in low-risk tumors [6]. Our group found that PCa innervation was higher on the proximal cancer surroundings than within PCa. Moreover, sympathetic ND was lower in PCa than in non-neoplastic prostate [5].

The authors proposed that tumors with higher sympathetic innervation were more likely to develop metastases and castration resistance, and implied that noradrenaline was the important neurotransmitter that regulated the late stage of PCa by AdrB2. A study by Magnon et al. revealed that sympathetic innervation regulated the early phase of tumor development and the parasympathetic nervous system stimulated the late stages of PCa. They also reported that ND correlated with a poor clinical outcome [6]. Data from other studies showed the correlation between sympathetic fibers ND and biochemical failure after prostatectomy, and that adrenergic signaling reactivated dormant PCa cells in the bone marrow [7, 8].

Tumor innervation parameters may become one of the additional prognostic factors, but further studies are necessary. Studies on small core-needle biopsy material or even bigger tissue samples seem to be insufficient for the assessment of the prognostic value of ND in PCa because of tumors heterogeneity and consecutive treatment-related changes in the neoplastic population.

Finally, Dwivedi et al. reported that among adrenergic receptors, the expression of β2ADR was the most upregulated in PCa compared to normal adjacent tissue. Moreover, in vitro experiments revealed that elevated noradrenaline levels contributed to neuroendocrine differentiation in androgen-positive and negative cell lines. Thus, the disruption of neurotransmission by targeting the noradrenaline-ADRβ2 axis may be a new effective therapeutic target. In this study, propranolol led to the inhibition of the morphological features of neuroendocrine differentiation, and inhibited the progression of PCa. Moreover, in the orthotopic tumor model, treatment with propranolol and castration significantly reduced tumor growth compared to castration alone or the control group [2]. Propranolol also affects cellular proliferation, apoptosis, inhibits angiogenesis, and regulates the immune system. The previous studies on PCa showed that chemical and surgical disruption of sympathetic signaling inhibits tumor growth, adrenergic nerves activate the angio-metabolic switch, and Adrβ2-cAMP-PKA cascade contributes to neuroendocrine differentiation and neuropeptide outgrowth [6, 9–11]. Thus, the reduction of adrenergic neurotransmission by β-blockers seems to be a promising treatment option for PCa cancer [9]. Zahlanka et al. found that among long-term β-blockers users, onlyatenolol was connected to a significant reduction in PCa risk on biopsy [12].
Despite an increasing number of studies on PCa neurobiology, the role of the autonomic nervous system, since the first study by Ayala et al., still needs further investigation. Dwivedy et al. experiments evaluating the role of β-blockers in the disruption of noradrenaline-driven neuroendocrine differentiation in PCa revealed new important data, which may change clinical attitude and therapeutic approach in the future.

DATA AVAILABILITY
Data are available to the journal and the publisher upon request.

REFERENCES
1. Senga SS, Grose RP. Hallmarks of cancer—the new testament. Open Biol. 2021;11:200358.
2. Dwivedi S, Bautista M, Shrestha S, Elhasasna H, Chaphekar T, Vizeacoumar FS, et al. Sympathetic signaling facilitates progression of neuroendocrine prostate cancer. Cell Death Discov. 2021;7:364.
3. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008;14:603–603.
4. Sejda A, Sigorski D, Gulczyński J, Wesołowski W, Iżycka-Świeżewska E. Complexity of neural component of tumor microenvironment in prostate cancer. Pathobiology. 2020;87:87–99.
5. Sigorski D, Gulczyński J, Sejda A, Rogowski W, Iżycka-Świeżewska E. Investigation of neural microenvironment in prostate cancer in context of neural density, perineural invasion, and neuroendocrine profile of tumors. Front Oncol. 2021;11:2602.
6. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361–1236361.
7. Reeves FA, Battye S, Roth H, Peters JS, Hovens C, Costello AJ, et al. Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. J Clin Neurosci. 2019;63:213–9.
8. Decker AM, Jung Y, Cackowski FC, Yumoto K, Wang J, Taichman RS. Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow. Mol Cancer Res. 2017;15:1644.
9. Zhao Y, Li W. Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. Asian J Androl. 2019;21:253–9.
10. Zahalka AH, Amal-Estapé A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:32–6.
11. Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, et al. Influence of the neural microenvironment on prostate cancer. Prostate. 2018;78:128–39.
12. Zahalka AH, Fram E, Lin W, Mohn L, Frenette PS, Agalliu I, et al. Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population. Urol Oncol. 2020;38:794.e11–794.e16.

AUTHOR CONTRIBUTIONS
DS—designed and drafted the paper, EI-Ś—revised the paper.

FUNDING
The study was funded by the University of Warmia and Mazury in Olsztyn.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to D. Sigorski.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Fig. 1 Propranolol inhibits adrenergic signaling and neuroendocrine differentiation (NED) in prostate cancer (created with smart.servier.com). ADRβ2 Adrenoceptor Beta 2.